Cargando…
Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer
SIMPLE SUMMARY: Recurrent ovarian-cancer patients face low 5-year survival rates despite chemotherapy. Oncologists may choose from a variety of guideline-recommended second-line therapeutic options without knowing which one works best. Thus, therapy alterations and adjustments are often required. We...
Autores principales: | Hoffmann, Oliver Ingo, Regenauer, Manuel, Czogalla, Bastian, Brambs, Christine, Burges, Alexander, Mayer, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9103312/ https://www.ncbi.nlm.nih.gov/pubmed/35565408 http://dx.doi.org/10.3390/cancers14092279 |
Ejemplares similares
-
Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer
por: Dötzer, Katharina, et al.
Publicado: (2021) -
Combined Expression of HGFR with Her2/neu, EGFR, IGF1R, Mucin-1 and Integrin α2β1 Is Associated with Aggressive Epithelial Ovarian Cancer
por: Czogalla, Bastian, et al.
Publicado: (2022) -
Carbonic anhydrase XII as biomarker and therapeutic target in ovarian carcinomas
por: Hiepp, Lisa, et al.
Publicado: (2022) -
Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer
por: Dötzer, Katharina, et al.
Publicado: (2019) -
MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use
por: Nana-Sinkam, S Patrick, et al.
Publicado: (2014)